Carfilzomib vs Ixazomib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Carfilzomib

Marketed by Amgen and partners

Approved in Multiple Myelomasmall molecule
Partial signal

NCT01080391 · Phase 3 · completed

The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).

Next expected readout: November 2026 · NCT04973605 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)

Result source: NCT03158688

Ixazomib

Marketed by Takeda Pharmaceutical Company and partners

Approved in Multiple Myelomasmall molecule
Reliable signal

NCT01564537 · Phase 3 · completed

Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).

Next expected readout: March 2027 · NCT04068597 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)

Result source: NCT02312258

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarfilzomibIxazomib
PFS, median26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results
OS, median10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results
53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results
ORR82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284
78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results
VGPR or better72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results
48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374
MRD negativity18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565
59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results

PFS, median

Carfilzomib
26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
Ixazomib
20.6 vs 14.7+5.9 vs placebon 360NCT01564537
13 other results

OS, median

Carfilzomib
10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results
Ixazomib
53.6 vs 51.6+2 vs placebon 360NCT01564537
6 other results

ORR

Carfilzomib
82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284
Ixazomib
78.3% vs 71.5%+6.8 vs placebon 360NCT01564537
10 other results

VGPR or better

Carfilzomib
72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results
Ixazomib
48.1% vs 39%+9.1 vs placebon 360NCT01564537
2 other results
  • 50% 4 mg + 25 mg + 40 mg · n 32 · Phase 2 · primary NCT02917941
  • 42.2% vs 43.6% n 45 · Phase 4 · secondary NCT03416374

MRD negativity

Carfilzomib
18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565
Ixazomib
59% vs 50%+9 vs placebowk 72 · n 335NCT01850524
3 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
41 other shared endpoints and safety

Coverage. Carfilzomib: 45 of 45 rows · Ixazomib: 45 of 45 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarfilzomib
Rows use multiple source trials
Ixazomib
Rows use multiple source trials
Complete
responder rate · % of participants
44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasonea,b
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
2 other source trials
28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasone
NCT03158688 · Phase 3 · combination
25.9% (n=478) vs 23.1% (n=477) Bortezomib, Melphalan, Prednisone
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
26% (n=351) vs 14% (n=354) placeboa,b
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response
time to event · months
28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) monthsb
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
4 other source trials
7.2 vs 9.5 placebo months
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
NA vs NA Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
21.3 vs 10.4 Bortezomib months
NCT01568866 · Phase 3 · combination
NA vs 16.6 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
26 vs 21.7 placebo monthsb
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
3 other source trials
50.6 vs 37.5 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
28.03 vs 15.31 Bortezomib + Lenalidomide + Dexamethasone months
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
14.8 vs 14.3 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Duration of Response
time to event · months
No placebo or comparator arm
NA monthsc,d,b
NCT03412565 · Phase 2 · combination
show 2 more doses
NA months
NCT03412565 · Phase 2 · combination
NA months
NCT03412565 · Phase 2 · combination
22.92 months*c,d,b
NCT02389517 · Phase 2 · registry result, not featured evidence · combination · converted to months from 1.91 years as posted
show 1 more dose
23.76 months*
NCT02389517 · Phase 2 · registry result, not featured evidence · converted to months from 1.98 years as posted
EORTC QLQ-C30 GHS
absolute change · score
65.1 vs 62.9 Bortezomib, Melphalan, Prednisone score @ 48wkd,e,b
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
-4.1 vs -1.7 placebo scored,e,b
NCT02181413 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 10
67.98 vs 68.38 Carfilzomib and Dexamethasone score @ 36wkd,e
Cycle 10
NCT03158688 · Phase 3 · combination
-1.6 vs 2 placebo score @ 36wkd,e
Cycle 10
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 11
68.52 vs 67.42 Carfilzomib and Dexamethasone score @ 40wkd,e
Cycle 11
NCT03158688 · Phase 3 · combination
0.2 vs 3.9 placebo score @ 40wkd,e
Cycle 11
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 12
67.47 vs 65.13 Carfilzomib and Dexamethasone score @ 44wkd,e
Cycle 12
NCT03158688 · Phase 3 · combination
0.3 vs 3.9 placebo score @ 44wkd,e
Cycle 12
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 13
67 vs 67.49 Carfilzomib and Dexamethasone score @ 48wkd,e
Cycle 13
NCT03158688 · Phase 3 · combination
-0.5 vs 4.2 placebo score @ 48wkd,e
Cycle 13
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 14
66.12 vs 67.66 Carfilzomib and Dexamethasone score @ 52wkd,e
Cycle 14
NCT03158688 · Phase 3 · combination
-1.1 vs 3.1 placebo score @ 52wkd,e
Cycle 14
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 15
67.61 vs 69.34 Carfilzomib and Dexamethasone score @ 56wkd,e
Cycle 15
NCT03158688 · Phase 3 · combination
-0.7 vs 2.2 placebo score @ 56wkd,e
Cycle 15
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 16
66.41 vs 68.21 Carfilzomib and Dexamethasone score @ 60wkd,e
Cycle 16
NCT03158688 · Phase 3 · combination
0.5 vs 2.5 placebo score @ 60wkd,e
Cycle 16
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 17
69.81 vs 69.44 Carfilzomib and Dexamethasone score @ 64wkd,e
Cycle 17
NCT03158688 · Phase 3 · combination
-0.2 vs 2.4 placebo score @ 64wkd,e
Cycle 17
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 18
66.29 vs 66.67 Carfilzomib and Dexamethasone score @ 68wkd,e
Cycle 18
NCT03158688 · Phase 3 · combination
1.7 vs 0.5 placebo score @ 68wkd,e
Cycle 18
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 19
68 vs 69.68 Carfilzomib and Dexamethasone score @ 72wkd,e
Cycle 19
NCT03158688 · Phase 3 · combination
1.1 vs 1.6 placebo score @ 72wkd,e
Cycle 19
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 2
61 vs 64.35 Carfilzomib and Dexamethasone score @ 4wkd,e
Cycle 2
NCT03158688 · Phase 3 · combination
-0.1 vs 1.7 placebo score @ 4wkd,e
Cycle 2
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 20
66.43 vs 71.04 Carfilzomib and Dexamethasone score @ 76wkd,e
Cycle 20
NCT03158688 · Phase 3 · combination
0.4 vs 1.1 placebo score @ 76wkd,e
Cycle 20
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 21
67.42 vs 70.94 Carfilzomib and Dexamethasone score @ 80wkd,e
Cycle 21
NCT03158688 · Phase 3 · combination
1.3 vs 1.5 placebo score @ 80wkd,e
Cycle 21
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 22
67.51 vs 68.52 Carfilzomib and Dexamethasone score @ 84wkd,e
Cycle 22
NCT03158688 · Phase 3 · combination
1 vs 1.6 placebo score @ 84wkd,e
Cycle 22
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 23
66.67 vs 69.52 Carfilzomib and Dexamethasone score @ 88wkd,e
Cycle 23
NCT03158688 · Phase 3 · combination
0.9 vs 2.1 placebo score @ 88wkd,e
Cycle 23
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 24
68 vs 68.1 Carfilzomib and Dexamethasone score @ 92wkd,e
Cycle 24
NCT03158688 · Phase 3 · combination
2.3 vs -0.3 placebo score @ 92wkd,e
Cycle 24
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 25
66.21 vs 67.93 Carfilzomib and Dexamethasone score @ 96wkd,e
Cycle 25
NCT03158688 · Phase 3 · combination
0.3 vs 0 placebo score @ 96wkd,e
Cycle 25
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 26
66.12 vs 70.71 Carfilzomib and Dexamethasone score @ 100wkd,e
Cycle 26
NCT03158688 · Phase 3 · combination
0.9 vs 2.8 placebo score @ 100wkd,e
Cycle 26
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 3
63.1 vs 66.13 Carfilzomib and Dexamethasone score @ 8wkd,e
Cycle 3
NCT03158688 · Phase 3 · combination
-1.2 vs 2.1 placebo score @ 8wkd,e
Cycle 3
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 32
67.91 vs 66.67 Carfilzomib and Dexamethasone score @ 124wkf,d,g
Cycle 32
NCT03158688 · Phase 3 · combination
50 vs 50 Carfilzomib + Lenalidomide + Dexamethasone score @ 128wkf,d,g
Cycle 32
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS
absolute change · score
Cycle 4
63.47 vs 66.67 Carfilzomib and Dexamethasone score @ 12wkd,e
Cycle 4
NCT03158688 · Phase 3 · combination
-0.6 vs 1.5 placebo score @ 12wkd,e
Cycle 4
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 5
64.45 vs 67.62 Carfilzomib and Dexamethasone score @ 16wkd,e
Cycle 5
NCT03158688 · Phase 3 · combination
0.6 vs 1.8 placebo score @ 16wkd,e
Cycle 5
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 6
65.92 vs 68.06 Carfilzomib and Dexamethasone score @ 20wkd,e
Cycle 6
NCT03158688 · Phase 3 · combination
-1.5 vs 1 placebo score @ 20wkd,e
Cycle 6
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 7
65.73 vs 69.33 Carfilzomib and Dexamethasone score @ 24wkd,e
Cycle 7
NCT03158688 · Phase 3 · combination
-0.7 vs 3.1 placebo score @ 24wkd,e
Cycle 7
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 8
66.34 vs 69.44 Carfilzomib and Dexamethasone score @ 28wkd,e
Cycle 8
NCT03158688 · Phase 3 · combination
-0.4 vs 0.9 placebo score @ 28wkd,e
Cycle 8
NCT02312258 · Phase 3
EORTC QLQ-C30 GHS
absolute change · score
Cycle 9
67.82 vs 65.72 Carfilzomib and Dexamethasone score @ 32wkd,e
Cycle 9
NCT03158688 · Phase 3 · combination
0.1 vs 1.4 placebo score @ 32wkd,e
Cycle 9
NCT02312258 · Phase 3
MRD Negative
responder rate · % of participants
No placebo or comparator arm
25.4% (n=67)c,d,b
NCT03412565 · Phase 2 · combination
show 2 more doses
27.3% (n=66)
NCT03412565 · Phase 2 · combination
21.5% (n=65)
NCT03412565 · Phase 2 · combination
18% (n=11) @ 52wkc,d,b
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
31% (n=13) @ 52wk
NCT02389517 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
62.9% (n=240)20/70 mg/m² once weeklyc,h,d,b
NCT02412878 · Phase 3 · combination
show 1 more dose
40.8% (n=238)20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
84.4% (n=32)4 mg + 25 mg + 40 mgh,d,b
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
3 other source trials
49% (n=73)
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
63% (n=35) @ 48wk
NCT01864018 · Phase 1/2 · registry result, not featured evidence · combination
28% (n=18)90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
ORR
absolute value · percentage points
No placebo or comparator arm
16.7% (n=42)c,i,d,b
NCT00511238 · Phase 2
show 1 more dose
23.7% (n=257)
NCT00511238 · Phase 2 · pooled
48% (n=25)4 mgi,d,b
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
NA months20/70 mg/m² once weeklyc,d,e,b
NCT02412878 · Phase 3 · combination
show 1 more dose
NA months20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
NA monthsd,e,b
NCT03748953 · Phase 3 · registry result, not featured evidence
9 other source trials
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence
NA months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
23.2 months90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
11.2 months20/70 mg/m² once weeklyc,d,e,b
NCT02412878 · Phase 3 · combination
show 1 more dose
7.6 months20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
21.3 monthsd,e,b
NCT03748953 · Phase 3 · registry result, not featured evidence
7 other source trials
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
NA months
NCT02389517 · Phase 2 · registry result, not featured evidence
22.05 months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
23.5 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
14.2 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
23 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
5.2 months90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
PFS2
time to event · months
47.18 vs 35.58 Carfilzomib + Dexamethasone monthsc,d,e,b
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more dose
47.18 vs 32.36 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
84 vs 80.4 placebo monthsd,e,b
NCT02181413 · Phase 3
1 other source trial
51.3 vs 50.3 placebo months
NCT02312258 · Phase 3
Time to Progression
time to event · months
NA vs 20.27 Carfilzomib + Dexamethasone monthsb
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
NA vs 17.5 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
22.4 vs 17.6 placebo monthsb
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
4 other source trials
45.8 vs 26.8 placebo months
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
26.6 vs 21.4 placebo months
NCT02181413 · Phase 3
17.8 vs 9.6 placebo months
NCT02312258 · Phase 3
8.4 vs 5.1 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Time to Progression
time to event · months
No placebo or comparator arm
9.4 months20/70 mg/m²c,j,k,b
NCT00531284 · Phase 1/2
show 18 more doses
1 months20/70 mg/m²
NCT00531284 · Phase 1/2
1.6 months20/70 mg/m²
NCT00531284 · Phase 1/2
NA months20/70 mg/m²
NCT00531284 · Phase 1/2
6.9 months20/56 mg/m²
NCT00531284 · Phase 1/2
11.5 months20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
NA months20/56 mg/m²
NCT00531284 · Phase 1/2
1.6 months20/56 mg/m²
NCT00531284 · Phase 1/2
NA months20/56 mg/m²
NCT00531284 · Phase 1/2
4.6 months20/45 mg/m²
NCT00531284 · Phase 1/2
4.6 months20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
1.6 months20/45 mg/m²
NCT00531284 · Phase 1/2
1.6 months45 mg/m²
NCT00531284 · Phase 1/2
5.2 months20/36 mg/m²
NCT00531284 · Phase 1/2
1.8 months20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
1.7 months36 mg/m²
NCT00531284 · Phase 1/2
1.8 months20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
1.8 months20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
5.1 months20 mg/m² Bolus
NCT00531284 · Phase 1/2
21.3 monthsj,k,b
NCT03748953 · Phase 3 · registry result, not featured evidence
4 other source trials
22.57 months4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
30.9 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
16.8 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
32.2 months
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
Time to Response
time to event · months
1.4 vs 1.5 Carfilzomib and Dexamethasone monthsd,b
NCT03158688 · Phase 3 · combination
1.02 vs 1.87 placebo monthsd,b
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
2 vs 1.1 Pomalidomide months4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
Time to Response
time to event · months
No placebo or comparator arm
2.6 monthsc,l,d,b
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
2.8 months
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
2.1 monthsl,d,b
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
VGPR or Better
responder rate · % of participants
No placebo or comparator arm
77.6% (n=67)c,d,b
NCT03412565 · Phase 2 · combination
show 3 more doses
71.6% (n=67)
NCT03412565 · Phase 2 · combination
77.3% (n=66)
NCT03412565 · Phase 2 · combination
80% (n=65)
NCT03412565 · Phase 2 · combination
50% (n=32)4 mg + 25 mg + 40 mgd,b
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
Dropout rate
1%m
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
0.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
89.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
5.4%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
8.8%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
67.3%
NCT03158688 · Phase 3 · combination
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
77.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
57.1%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/45 mg/m²
NCT00531284 · Phase 1/2
85.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/45 mg/m²
NCT00531284 · Phase 1/2
100%45 mg/m²
NCT00531284 · Phase 1/2
100%20/36 mg/m²
NCT00531284 · Phase 1/2
85.7%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%36 mg/m²
NCT00531284 · Phase 1/2
96.9%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20 mg/m² Bolus
NCT00531284 · Phase 1/2
91.3%Carfilzomib (A0)
NCT00511238 · Phase 2
85%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
58.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
74.3%20 mg/m²
NCT00530816 · Phase 2
71.2%20 mg/m²
NCT00530816 · Phase 2
92.3%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
65.3%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
16.2%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
78.6%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
41.4%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
11.1%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
19.7%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01775553 · Phase 2 · registry result, not featured evidence
20.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
80%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
2.8%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
93.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
95.5%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
66.7%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
100%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
28.1%n
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
49.3%Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
18.5%
NCT02181413 · Phase 3
n/a: no completion milestone
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
0%
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
3%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
2.8%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
10.8%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneIxazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
30%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
22.7%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
0%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
0%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
0%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
14.3%
NCT02440464 · Phase 2 · registry result, not featured evidence
70.6%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
33.3%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
95%
NCT02499081 · Phase 2 · registry result, not featured evidence
0%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
25%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—m
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
—
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
16.2%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
20.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
—20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
—20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
—
NCT03158688 · Phase 3 · combination
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
—Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
14.3%20/70 mg/m²
NCT00531284 · Phase 1/2
0%20/70 mg/m²
NCT00531284 · Phase 1/2
27.3%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
25%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
20%20/56 mg/m²
NCT00531284 · Phase 1/2
20.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/45 mg/m²
NCT00531284 · Phase 1/2
28.6%45 mg/m²
NCT00531284 · Phase 1/2
0%20/36 mg/m²
NCT00531284 · Phase 1/2
14.3%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
0%36 mg/m²
NCT00531284 · Phase 1/2
10.8%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
0%20 mg/m² Bolus
NCT00531284 · Phase 1/2
28.3%Carfilzomib (A0)
NCT00511238 · Phase 2
12.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
10%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
17.1%20 mg/m²
NCT00530816 · Phase 2
22%20 mg/m²
NCT00530816 · Phase 2
—Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
15.5%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
—
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
—low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
—high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT01775553 · Phase 2 · registry result, not featured evidence
9.1%
NCT01351623 · Phase 2 · registry result, not featured evidence
37.5%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
8.3%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
40%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
25%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
0%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
13.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
14.6%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
—n
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT02181413 · Phase 3
—
NCT02312258 · Phase 3
—
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
—
NCT03748953 · Phase 3 · registry result, not featured evidence
—
NCT02619682 · Phase 2 · registry result, not featured evidence
—Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
0%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
13%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
15%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
4.5%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
—
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
—Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
—Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
—
NCT02440464 · Phase 2 · registry result, not featured evidence
32.4%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
—4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
—2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
—
NCT02499081 · Phase 2 · registry result, not featured evidence
—4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
65.3%m
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
58.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
72.9%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
58.7%Carfilzomib
NCT01568866 · Phase 3
—Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
49.6%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
43.4%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
68.5%
NCT03158688 · Phase 3 · combination
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
33.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
71.4%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
54.5%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
37.5%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/56 mg/m²
NCT00531284 · Phase 1/2
45.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
35.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
83.3%20/45 mg/m²
NCT00531284 · Phase 1/2
57.1%45 mg/m²
NCT00531284 · Phase 1/2
50%20/36 mg/m²
NCT00531284 · Phase 1/2
57.1%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%36 mg/m²
NCT00531284 · Phase 1/2
41.5%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%20 mg/m² Bolus
NCT00531284 · Phase 1/2
43.5%Carfilzomib (A0)
NCT00511238 · Phase 2
47.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
38.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
34.3%20 mg/m²
NCT00530816 · Phase 2
30.5%20 mg/m²
NCT00530816 · Phase 2
38.5%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
22.4%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
37.7%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
32.5%20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
55.3%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
49.6%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
39.1%
NCT02969837 · Phase 2 · registry result, not featured evidence
42.2%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
39.4%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
47.4%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01775553 · Phase 2 · registry result, not featured evidence
63.6%
NCT01351623 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
41.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
33.3%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
65.2%MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
45.7%Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
16.7%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
26.7%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
39.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
33.3%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
56.8%n
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 40 more results
—Ixazomib + LenDex
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
65.4%Ixazomib + LenDex (Exposure ≥19 Cy
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
73%Ixazomib+ LenDex (Exposure Up to 1
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3
27.4%
NCT02181413 · Phase 3
23.7%
NCT02312258 · Phase 3
37.8%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
31.4%
NCT03748953 · Phase 3 · registry result, not featured evidence
13.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
48.5%Arm A (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm B (Ixazomib Citrate and Dexame
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
31.4%Arm C (Higher-dose Ixazomib Citrat
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
38.9%Arm D (Ixazomib Citrate, Dexametha
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
58.3%Arm E (Ixazomib Citrate, Cyclophos
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
44.4%Ixazomib Combination Therapy
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
52.2%Ixazomib Monotherapy
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
25%Arm I (Ixazomib Citrate, Lenalidom
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
9.1%Arm II (Lenalidomide)
NCT02389517 · Phase 2 · registry result, not featured evidence
8.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
74.1%Arm A (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
45.5%Arm B (Ixazomib and Dexamethasone)
NCT02765854 · Phase 2 · registry result, not featured evidence
47.6%Arm C (Ixazomib, Dexamethasone, Le
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
55.6%4 mg
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
52.4%
NCT02440464 · Phase 2 · registry result, not featured evidence
35.3%4 mg + 25 mg + 40 mg
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
66.7%4 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
66.7%3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
0%2.3 mg
NCT02168101 · Phase 2 · registry result, not featured evidence
47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 +
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
40%
NCT02499081 · Phase 2 · registry result, not featured evidence
44%4 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
57.1%3 mg
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
0%90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—90 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
42.1%80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—80 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
66.7%70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
—70 mg/m^2
NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
m
diarrhoea 43.4%
anaemia 42.3%
neutropenia 40.1%
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 62 more results
anaemia 56.1% (placebo 47.1%)
thrombocytopenia 36.9% (placebo 28.1%)
pyrexia 26.1% (placebo 18.3%)
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
infusion related reaction 45.2%
upper respiratory tract infection 41.2%
diarrhoea 40.7%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
anaemia 42.3%
diarrhoea 36.1%
fatigue 32.2%
NCT01568866 · Phase 3
20/70 mg/m² once weekly
anaemia 29%
hypertension 24.4%
pyrexia 23.1%
NCT02412878 · Phase 3 · combination
20/27 mg/m² twice weekly
anaemia 31.1%
diarrhoea 21.7%
hypertension 20.9%
NCT02412878 · Phase 3 · combination
thrombocytopenia 38.6%
anaemia 36.7%
hypertension 36.7%
NCT03158688 · Phase 3 · combination
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · combination
thrombocytopenia 51.5%
anaemia 37.9%
hypertension 34.8%
NCT03412565 · Phase 2 · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · combination
20/70 mg/m²
pyrexia 71.4%
blood creatinine increased 57.1%
chills 57.1%
NCT00531284 · Phase 1/2
20/70 mg/m²
fatigue 100%
thrombocytopenia 100%
anaemia 50%
NCT00531284 · Phase 1/2
20/70 mg/m²
nausea 54.5%
fatigue 45.5%
anaemia 27.3%
NCT00531284 · Phase 1/2
20/56 mg/m²
pyrexia 100%
asthenia 66.7%
cough 66.7%
NCT00531284 · Phase 1/2
20/56 mg/m² + Dex
fatigue 62.5%
pyrexia 50%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/56 mg/m²
pyrexia 50%
anaemia 40%
constipation 40%
NCT00531284 · Phase 1/2
20/56 mg/m²
fatigue 58.3%
nausea 54.2%
pyrexia 54.2%
NCT00531284 · Phase 1/2
20/45 mg/m²
fatigue 100%
blood creatinine increased 66.7%
cancer pain 66.7%
NCT00531284 · Phase 1/2
20/45 mg/m² + Dex
fatigue 64.3%
cough 57.1%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/45 mg/m²
chills 50%
fatigue 50%
hypoaesthesia 50%
NCT00531284 · Phase 1/2
45 mg/m²
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT00531284 · Phase 1/2
20/36 mg/m²
fatigue 75%
nausea 75%
anaemia 50%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
asthenia 57.1%
headache 57.1%
nausea 57.1%
NCT00531284 · Phase 1/2
36 mg/m²
chest wall pain 33.3%
dyspnoea 33.3%
nausea 33.3%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
fatigue 58.5%
nausea 43.1%
anorexia 40%
NCT00531284 · Phase 1/2
20/27 mg/m² Bolus
back pain 50%
fatigue 50%
abnormal dreams 25%
NCT00531284 · Phase 1/2
20 mg/m² Bolus
hypomagnesaemia 66.7%
anxiety 33.3%
constipation 33.3%
NCT00531284 · Phase 1/2
anaemia 73.9%
fatigue 69.6%
thrombocytopenia 50%
NCT00511238 · Phase 2
fatigue 48.9%
anaemia 45.9%
nausea 44.7%
NCT00511238 · Phase 2 · pooled
20/27 mg/m²
fatigue 54.3%
nausea 44.3%
anaemia 35.7%
NCT00530816 · Phase 2 · pooled
20 mg/m²
fatigue 62.9%
nausea 60%
vomiting 42.9%
NCT00530816 · Phase 2
20 mg/m²
fatigue 71.2%
nausea 54.2%
dyspnoea 49.2%
NCT00530816 · Phase 2
cough 42.3%
anaemia 36.5%
pyrexia 26.9%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
cough 26.5%
diarrhoea 18.4%
hypertension 18.4%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
20/56 mg/m^2 once weekly
neutropenia 29.1%
anaemia 25.1%
hypertension 21.5%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
20/27 mg/m^2 twice weekly
neutropenia 31.6%
hypertension 24.2%
anaemia 23.8%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
anaemia 61.8%
platelet count decreased 48.8%
upper respiratory tract infection 48.8%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
anaemia 35.4%
pyrexia 35.4%
nausea 35.2%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
fatigue 63%
diarrhea 45.7%
edema limbs 37%
NCT02969837 · Phase 2 · registry result, not featured evidence
lymphocyte count decreased 100%
hypoalbuminemia 93.3%
platelet count decreased 93.3%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
low-dose
anemia 59.1%
fatigue 59.1%
platelet count decreased 42.4%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
high-dose
anemia 66.7%
fatigue 57.9%
platelet count decreased 50.9%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
anemia 61.5%
hypertension 53.8%
platelet count decreased 53.8%
NCT01775553 · Phase 2 · registry result, not featured evidence
diarrhea 65.9%
nausea 59.1%
fatigue 54.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
thrombocytopenia 62.5%
abdominal pain 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 58.3%
constipation 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 70%
fatigue 60%
nausea 60%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 50%
dyspnoea 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
fatigue 50%
dyspnoea 37.5%
NCT00721734 · Phase 2 · registry result, not featured evidence
56mg/m2/Dose
anxiety 33.3%
hyperkalemia 33.3%
hypertension 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
45mg/m2/Dose
lymphocyte count decreased 66.7%
skin infection 66.7%
alanine aminotransferase increased 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
lymphocyte count decreased 73.9%
neutrophil count decreased 65.2%
white blood cell decreased 60.9%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
Dose Level 0
anemia 100%
cd4 lymphocytes decreased 100%
lymphocyte count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 1
anemia 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 2
hypotension 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 3
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
platelet count decreased 100%
lymphocyte count decreased 91.4%
white blood cell decreased 91.4%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
88 mg/m²
headache 66.7%
fatigue 50%
insomnia 50%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
upper respiratory tract infection 80%
diarrhoea 60%
fatigue 60%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
fatigue 52.8%
nausea 40.4%
insomnia 32.6%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
56 mg/m²
anaemia 66.7%
arthralgia 66.7%
cardiac murmur 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
45 mg/m²
fatigue 100%
back pain 66.7%
diarrhoea 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
n
diarrhoea 51.5% (placebo 42.6%)
constipation 34.6% (placebo 27.6%)
anaemia 34.1% (placebo 29.2%)
NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3
show 32 more results
diarrhoea 77% (placebo 30%)
oedema peripheral 55.5% (placebo 32.5%)
constipation 48.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
diarrhoea 41.7% (placebo 30%)
oedema peripheral 40.5% (placebo 32.5%)
constipation 36.2% (placebo 38.1%)
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
nausea 39.1% (placebo 15.4%)
diarrhoea 34.3% (placebo 23.6%)
arthralgia 26.6% (placebo 16.6%)
NCT02181413 · Phase 3
nausea 27.9% (placebo 8.3%)
diarrhoea 23.9% (placebo 12.7%)
vomiting 23.9% (placebo 4%)
NCT02312258 · Phase 3
diarrhoea 28.9%
white blood cell count decreased 24.4%
platelet count decreased 20%
NCT03416374 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 40% (placebo 25%)
diarrhoea 34.3% (placebo 25%)
vomiting 25.7% (placebo 0%)
NCT03748953 · Phase 3 · registry result, not featured evidence
lymphocyte decreased 36.7%
lymphocyte decreased 33.3%
wbc decreased 33.3%
NCT02619682 · Phase 2 · registry result, not featured evidence
fatigue 87.9%
nausea 84.8%
platelet count decreased 81.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.3%
peripheral sensory neuropathy 88.6%
platelet count decreased 74.3%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 82.9%
platelet count decreased 80%
peripheral sensory neuropathy 77.1%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
fatigue 94.4%
diarrhea 80.6%
nausea 77.8%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anemia 91.7%
fatigue 91.7%
lymphocyte count decreased 91.7%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
anaemia 33.3%
upper respiratory tract infection 33.3%
aspartate aminotransferase increased 22.2%
NCT02924272 · Phase 2 · registry result, not featured evidence · combination
hypertension 17.4%
upper respiratory tract infection 13%
ankle fracture 8.7%
NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy
diarrhea 95%
fatigue 50%
nausea 50%
NCT02389517 · Phase 2 · registry result, not featured evidence · combination
diarrhea 50%
fatigue 40.9%
upper respiratory infection 27.3%
NCT02389517 · Phase 2 · registry result, not featured evidence
platelet count decreased 91.7%
lymphocyte count decreased 83.3%
rash 83.3%
NCT02412228 · Phase 2 · registry result, not featured evidence · combination
pneumonia 33.3%
colitis 22.2%
upper respiratory infection 22.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
conjunctivits 36.4%
bone pain 18.2%
pneumonia 18.2%
NCT02765854 · Phase 2 · registry result, not featured evidence
thrombocytopenia 42.9%
neutropenia 19%
pneumonia 19%
NCT02765854 · Phase 2 · registry result, not featured evidence · combination
4 mg
diarrhoea 38.9%
peripheral sensory neuropathy 26.4%
fatigue 23.6%
NCT03170882 · Phase 2 · registry result, not featured evidence · combination
pyrexia 14.3% (placebo 4.5%)
myalgia 4.8% (placebo 0%)
upper respiratory tract infection 4.8% (placebo 0%)
NCT02440464 · Phase 2 · registry result, not featured evidence
4 mg + 25 mg + 40 mg
constipation 50%
upper respiratory tract infection 47.1%
diarrhoea 41.2%
NCT02917941 · Phase 2 · registry result, not featured evidence · combination
4 mg
thrombocytopenia 100%
anaemia 66.7%
aspartate aminotransferase increased 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
3 mg
gastritis 66.7%
thrombocytopenia 66.7%
abdominal pain 33.3%
NCT02168101 · Phase 2 · registry result, not featured evidence
2.3 mg
diarrhoea 100%
dry eye 66.7%
hypertension 66.7%
NCT02168101 · Phase 2 · registry result, not featured evidence
anaemia 30.6%
diarrhoea 30.6%
upper respiratory tract infection 25%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 33.3%
upper respiratory tract infection 26.9%
anaemia 24.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
neutropenia 47.1%
anaemia 32.4%
nausea 29.4%
NCT02046070 · Phase 2 · registry result, not featured evidence · combination
hyperglycemia 85%
hypoalbuminemia 80%
fatigue 75%
NCT02499081 · Phase 2 · registry result, not featured evidence
4 mg
anemia 76%
platelet count decreased 76%
neutrophil count decreased 68%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination
3 mg
anemia 85.7%
lymphocyte count decreased 85.7%
white blood cell decreased 85.7%
NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation context differs: prior_therapy differs (experienced versus naive).
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for both studies.
  5. eTreatment context has not been resolved for both arms.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gAssessment timepoints differ: 124 weeks versus 128 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iTrial phases differ: Phase 2 versus Phase 1/2.
  10. jTrial phases differ: Phase 1/2 versus Phase 3.
  11. kPopulation context differs: registered conditions differ.
  12. lTrial phases differ: Phase 4 versus Phase 2.
  13. mPopulation comparability has not been reviewed for 66 of these studies.
  14. nPopulation comparability has not been reviewed for 36 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carfilzomib

Disease Control 92.7% (n=396) vs 87.1% (n=396) Lenalidomide and Dexamethasone (Rd)
responder rate · % of participants
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Disease Control 28.7 vs 18.9 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 19.1% (n=157) vs 11.4% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 30 participants as posted
Clinical Benefit 31.2% (n=157) vs 20.9% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 49 participants as posted
VGPR or Better With MRD Negativity 29.6% (n=179) vs 13% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
33.5% (n=179) vs 13.8% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete Response With MRD Negativity 26.3% (n=179) vs 12.2% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
12.8% (n=312) vs 1.9% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · combination
Complete Renal 52% (n=25) vs 30.8% (n=13) Carfilzomib + Dexamethasone
responder rate · % of participants
CR Renal
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 13 Participants as posted
Time to Next Treatment NA vs 17.3 Carfilzomib and Dexamethasone months
time to event · months
PA DCO
NCT03158688 · Phase 3 · combination
TTP 95.3% (n=312) vs 90% (n=154) Carfilzomib and Dexamethasone @ 13wk
responder rate · % of participants
NCT03158688 · Phase 3 · combination
show 3 more results
86.4% (n=312) vs 79.4% (n=154) Carfilzomib and Dexamethasone @ 26wk
NCT03158688 · Phase 3 · combination
77.5% (n=312) vs 62.7% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · combination
68.5% (n=312) vs 45.1% (n=154) Carfilzomib and Dexamethasone @ 78wk
NCT03158688 · Phase 3 · combination
Sustained MRD Negative CR 0% (n=312) vs 0% (n=154) Carfilzomib and Dexamethasone
responder rate · % of participants
PA DCO
NCT03158688 · Phase 3 · combination
EORTC QLQ-C30 GHS 66.52 vs 65.23 Carfilzomib and Dexamethasone score @ 104wk
absolute change · score
Cycle 27
NCT03158688 · Phase 3 · combination
EORTC QLQ-C30 GHS 67.28 vs 63.22 Carfilzomib and Dexamethasone score @ 108wk
absolute change · score
Cycle 28
NCT03158688 · Phase 3 · combination

+ 72 further endpoints in the CSV export.

Ixazomib

Pain 50.5% (n=190) vs 51.3% (n=195) placebo
responder rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
Skeletal-related 10% (n=163) vs 14% (n=160) placebo
event rate · % of participants
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
25% (n=191) vs 14% (n=160) placebo
NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR 40% (n=395) vs 45% (n=261) placebo
responder rate · % of participants
VGPR
NCT02181413 · Phase 3
show 1 more result
34% (n=425) vs 37% (n=281) placebo
VGPR
NCT02312258 · Phase 3
Time to Next Treatment 33.1 vs 27.6 placebo months
time to event · months
NCT02181413 · Phase 3
show 1 more result
22.1 vs 16.1 placebo months
NCT02312258 · Phase 3
MRD Negative 17.3% (n=225) vs 19.4% (n=139) placebo
event count · % of participants
NCT02181413 · Phase 3 · converted to % from 39 Participants as posted
Sustained MRD Negative 94.9% (n=39) vs 92.6% (n=27) placebo
event count · % of participants
NCT02181413 · Phase 3 · converted to % from 37 Participants as posted
ECOG 0 vs 0.1 placebo score
absolute change · score
NCT02181413 · Phase 3
ECOG 0 vs 0 placebo score @ 4wk
absolute change · score
Cycle 2 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 8wk
absolute change · score
Cycle 3 Day 1
NCT02312258 · Phase 3
ECOG -0.1 vs 0 placebo score @ 12wk
absolute change · score
Cycle 4 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 16wk
absolute change · score
Cycle 5 Day 1
NCT02312258 · Phase 3
ECOG 0 vs 0 placebo score @ 20wk
absolute change · score
Cycle 6 Day 1
NCT02312258 · Phase 3

+ 104 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · Ixazomib's landscape